Results 171 to 180 of about 2,938,705 (290)

Rapid establishment of public sector COVID-19 test-and-treatment programmes across seven low- and middle-income countries: implementation strategies and program monitoring results. [PDF]

BMJ Glob Health
Boeke CE, Hamza N, Agwuocha C, Amako O, Detleuxay K, Gao M, Griffith BC, Gumulira Y, Urli Hodges E, Joseph J, Lufesi N, Macharia E, Mbewe N, McCarthy E, Mintah FO, Mukiibi M, Mulenga M, Ngwije A, Ofori-Boadu L, Okoli IU, Phongphila S, Ramers C, Regan S, Twinomujuni E, Rwagasore E, Tebor J, Udayakumar K, COVID-19 Treatment QuickStart Consortium.   +27 more
europepmc   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults. [PDF]

J Natl Cancer Inst
Flores-Toro J, Jagu S, Smith M, Shern J, Hawkins DS, Mardis ER, Rudzinski E, Alonzo TA, Beeles T, Ramirez N, Thomas DL, Cottrell CE, Parbhoo K, Janeway KA, Leary S, Fouladi M, Oberoi S, Venkatramani R, Irwin M, Laetsch TW, Chen KS, Bailey K, Davis JL, Sullivan MB, Boja E, Lowy D, Guidry Auvil JM, Wideman B, Kibbe W, Doroshow J, Reaman GH.   +30 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Facilitate behavior change among surgeons for infection prevention and stewardship: lessons learned from Asia. [PDF]

Antimicrob Steward Healthc Epidemiol
Apisarnthanarak A, Rukskul P, Mundy LM.
europepmc   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Evaluating rural healthcare workforce programs: Applying modified whole-of-person retention improvement framework in VHA programs. [PDF]

J Rural Health
Longacre MR, Kinney LM, Carluzzo KL, Watts BV, Schifferdecker KE.   +4 more
europepmc   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Effect of a Quality Improvement Initiative on Procedural Abortion Pain and Anxiety Using a Standardized Patient-Focused Sedation Options Counseling Guide. [PDF]

Cureus
Small SL, Emery JF, Hart V, de Jager E.
europepmc   +1 more source